Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, MicroRNA in disease regulation, Protein Degradation and Inhibitors, and RNA modifications and cancer.
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.
Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.
Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma.
The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges.
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.
The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
The genome of IMiD-refractory myeloma.
Pan-Cancer Analysis of Canonical and Modified miRNAs Enhances the Resolution of the Functional miRNAome in Cancer
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications.
(Distinct) origins of IgM myeloma.
A concurrent canonical and modified miRNAome pan-cancer study on TCGA and TARGET cohorts leads to an enhanced resolution in cancer
ADAR1 can drive Multiple Myeloma progression by acting both as an RNA editor of specific transcripts and as a DNA mutator of their cognate genes
ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
KRAS induces lung tumorigenesis through microRNAs modulation
Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma
PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways
Selective targeting of point-mutated KRAS through artificial microRNAs
A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies
MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC
A set of NF-κB–regulated microRNAs induces acquired TRAIL resistance in Lung cancer
Quaking and<i>miR-155</i>interactions in inflammation and leukemogenesis
Synthetic RNAs for Gene Regulation: Design Principles and Computational Tools
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation